Drugs / INV-1120
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04443088 | Jun 2020 → Dec 2026 expected | carcinoma, metastatic malignant neoplasm | Shenzhen Ionova Life Sciences Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INV-1120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04443088 ↗ |
| Modality | Small molecule | “INV-1120 is an investigational selective and potent small molecule indicated for the treatment of solid malignancies including, but not limited to colorectal, breast,...” NCT04443088 ↗ |
| Route | Oral | “Subjects will receive escalating doses of INV-1120 orally once a day” NCT04443088 ↗ |